Prognostic gene signature for AML
Source: NCBI BioProject (ID PRJNA162567)
Source: NCBI BioProject (ID PRJNA162567)
0 0
Project name: Homo sapiens
Description: Acute myeloid leukemia (AML) is a heterogeneous disease in respect of molecular aberrations and prognosis. We used gene expression profiling of 562 patients treated in the German AMLCG 1999 trial to develop a gene signature that predicts survival in AML.Overall design: Analysis of 562 samples (140 HGU-133plus2; 422 HGU-133A; 422 HGU-133B) from adult patients with acute myeloid leukemia (AML).
Data type: Transcriptome or Gene expression
Sample scope: Multiisolate
Relevance: Medical
Organization: Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU)
Last updated: 2012-04-27